For research teamsFind studies
Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
154studies shown
Showing 76-100 of 154
RecruitingNCT07424404

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Canada, France, Germany, Hungary, Japan, Poland, Romania, Spain, and the United States.

SchizophreniaOtherFrom 5 Years to 17 Years
Countries
Canada, France, Germany, Hungary, Japan, Poland, Romania, Spain, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
View study
RecruitingNCT06585787

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, the United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, and Ukraine.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
View study
RecruitingNCT07343193

Deprescribing Antipsychotics: a Multiple Case Study

This study is recruiting. It focuses on schizophrenia and currently lists participation information in France.

SchizophreniaOtherOver 18 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
View study
RecruitingNCT07003529

Role of Inferior Colliculi in Auditory Hallucinations

This study is recruiting. It focuses on schizophrenia and currently lists participation information in France.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Nīmes
Condition
Schizophrenia
View study
RecruitingNCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, the United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, and the United Kingdom.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, United Kingdom
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
View study
RecruitingNCT07029581

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Bulgaria, Czech Republic, France, Italy, Serbia, and the United States.

SchizophreniaOtherFrom 55 Years to 84 Years
Countries
Bulgaria, Czech Republic, France, Italy, Serbia, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
View study
RecruitingNCT05511363

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Bulgaria, Croatia, Czech Republic, France, Germany, Italy, Serbia, Slovakia, Spain, the United Kingdom, and the United States.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Bulgaria, Croatia, Czech Republic, France, Germany, Italy, Serbia, Slovakia, Spain, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
View study
RecruitingNCT06159673

ACP-204 in Adults With Alzheimer's Disease Psychosis

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, and the United States.

SchizophreniaOtherFrom 55 Years to 95 Years
Countries
Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
View study
France | Clinical Trials | HopeStage Research